FibroBiologics, Inc.

Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Hamid Khoja, Ph. D., the Company’s Chief Scientific Officer (the “Purchaser”), relating to the issuance and sale of 298,508 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the “Warrants”), in a private placement (the “Offering”). Pursuant to the SPA, the Company will issue the 298,508 shares of common stock and the accompanying Warrants to the Purchaser at an offering price of $1.675 per share and accompanying Warrant, which was equal to the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on September 14, 2026 of $1.55 per share plus $0.125 per Warrant. The gross proceeds to the Company from the Offering are expected to be approximately $0.5 million, before deducting estimated Offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes and working capital. The Offering is expected to close on September 15, 2026, subject to the satisfaction of customary closing conditions. The Warrants will be exercisable at any time after the date of issuance and will have an exercise price of $1.55 per share. The Warrants will expire on the five-year anniversary of the date of issuance and contain cashless exercise provisions. The Warrants also contain standard anti-dilution adjustments to the exercise price including for stock splits, stock dividends, rights offerings and pro rata distributions. The SPA contains customary representations, warranties and agreements by the Company and Purchaser and customary conditions to closing. The representations, warranties and covenants contained in the SPA were made only for purposes of the SPA and as of a specific date, were solely for the benefit of the parties to the SPA, and may be subject to limitations agreed upon by the contracting parties. The foregoing descriptions of the SPA and the Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the SPA and Warrant attached hereto as Exhibit 10.1 and Exhibit 4.1, respectively, which are incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities. The information contained above in Item 1.01 related to the Offering is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of the Purchaser in the SPA, the offer and sale of the securities to be issued in the Offering are being offered and sold pursuant to the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy the securities described herein. The maximum number of shares of Common Stock of the Company that may be issued through the exercise of the Warrants is 298,508 shares, subject to anti-dilution adjustments.